Intérêts du Cannabidiol dans l'épilepsie infantile : Syndromes de Dravet et Lennox-Gastaut

Details

Supervisors

Lambert, Didier

Faculty

Faculté de pharmacie et des sciences biomédicales

Degree label

Master [120] en sciences pharmaceutiques

Abstract

enThe Food and Drug Administration in the U.S. approved Epidiolex®, an oral solution made of highly purified cannabidiol as a treatment for the epileptic syndromes of Dravet and Lennox-Gastaut. This is the first treatment indicate for Dravet's syndrome. Clinical studies have shown a decrease in the frequency and the severity of seizures. This document defines Dravet's and Lennox-Gastaut's syndromes, presents cannabidiol and its properties, and discuss the interests of this new treatment compared to pre-existing antiepileptic drugs